Published • loading... • Updated
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
Ipsen said 60.8% of patients on corabotase had sustained effect at Week 24, with 82.8% reporting satisfaction.
- On Saturday, May 16, 2026, Ipsen presented the first corabotase data for moderate-to-severe glabellar lines at the Scale Symposium in Nashville, TN, involving 183 patients.
- Corabotase is an investigational recombinant neuroinhibitor, or RNITM, designed to increase receptor affinity and improve resistance to degradation for sustained muscle inhibition.
- At Week 24, 60.8% of patients treated with corabotase experienced sustained effect versus 36.7% for Dysport, with 82.8% rating satisfaction as "very satisfied" or "satisfied."
- Patients treated with corabotase showed a rapid onset of action of 0.84 days, with 66% demonstrating significant improvement at Week 4 compared to 0% with placebo.
- Professor of Dermatology Martina Kerscher noted the initial data are encouraging as Ipsen evaluates corabotase across three aesthetic indications in the LANTIC trial.
Insights by Ground AI
11 Articles
11 Articles
The Toronto Star+10 Reposted by 10 other sources
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect vs placebo and vs Dysport,…
·Toronto, Canada
Read Full ArticleCoverage Details
Total News Sources11
Leaning Left7Leaning Right3Center1Last UpdatedBias Distribution64% Left
Bias Distribution
- 64% of the sources lean Left
64% Left
L 64%
R 27%
Factuality
To view factuality data please Upgrade to Premium
